Body-Identical vs Synthetic HRT in Perimenopause: Differences, Safety, and Which to Ask For

What Body-Identical and Synthetic Mean in the Context of HRT

The terms body-identical and synthetic in the HRT conversation refer to whether the hormones in a given preparation are chemically identical to those produced by the human ovary or are structurally different molecules designed to produce similar effects. Body-identical hormones, also called bioidentical or natural hormones, have the same molecular structure as endogenous oestradiol and progesterone. They are derived from plant sources, typically wild yam or soy, and chemically processed to match the precise molecular structure of the hormones a woman's body produces naturally. The two most clinically relevant body-identical hormones are oestradiol (also written oestradiol or estradiol), which matches the primary oestrogen produced in the ovary, and micronised progesterone (sold as Utrogestan in the UK), which matches natural progesterone. Synthetic hormones are structurally different molecules engineered to produce oestrogenic or progestogenic effects while often offering other pharmacological properties such as oral bioavailability, longer half-life, or specific receptor selectivity. The most common synthetic oestrogen in HRT is conjugated equine oestrogen (CEE), derived from horse urine, while synthetic progestogens include norethisterone, levonorgestrel, norgestimate, medroxyprogesterone acetate (MPA), and dydrogesterone.

Body-Identical Oestradiol vs Conjugated Equine Oestrogen

For the oestrogen component of HRT, the most commonly used body-identical option is transdermal oestradiol, delivered as a gel, patch, or spray. Conjugated equine oestrogen (CEE), the oestrogen used in the large US Women's Health Initiative (WHI) trial that generated significant controversy about HRT safety in the early 2000s, is primarily taken orally. The differences between these two approaches are clinically meaningful. Transdermal oestradiol bypasses liver first-pass metabolism, meaning it does not cause the liver to produce elevated clotting factors that oral oestrogen does. This translates to a lower risk of deep vein thrombosis and pulmonary embolism with transdermal oestradiol compared to oral oestrogen. The WHI study used oral CEE and oral MPA, a combination that has a different safety profile from modern body-identical transdermal HRT, which is one reason the study's risk estimates do not map directly onto current prescribing practice. Body-identical oestradiol provides the same primary oestrogen as the ovaries produced naturally, which many practitioners argue is a more physiological approach. CEE contains a mixture of multiple conjugated oestrogens including oestrone sulphate, equilin sulphate, and others that are not identical to human oestrogens, though they are metabolically active and effective at managing menopausal symptoms.

Micronised Progesterone vs Synthetic Progestogens

The progestogen component of HRT is where the body-identical versus synthetic distinction has the most significant clinical implications. Micronised progesterone (Utrogestan) is identical to the progesterone produced by the corpus luteum during a normal cycle. It has a calming, anxiolytic effect via GABA receptor modulation, which is one reason many women report improved sleep and reduced anxiety when they switch from synthetic progestogens to micronised progesterone. It is also associated with fewer metabolic side effects: unlike synthetic progestogens, micronised progesterone does not adversely affect lipid profiles, blood pressure, or insulin sensitivity. Critically, the large French E3N study, which followed over 80,000 women, found that women using oestradiol combined with micronised progesterone had no increased breast cancer risk compared to non-users after five years, a markedly better finding than observed with synthetic progestogen combinations. Synthetic progestogens, including norethisterone and MPA, produce their progestogenic effects through progesterone receptors but also bind to androgen and glucocorticoid receptors, which can cause side effects including acne, bloating, low mood, fluid retention, and irritability. Not all synthetic progestogens carry the same risk or side-effect profile: dydrogesterone and progesterone-derived progestogens are considered more progesterone-selective and may be better tolerated than norethisterone derivatives.

Safety Profiles: What the Evidence Currently Shows

The overall safety comparison between body-identical and synthetic HRT is nuanced and depends on which safety outcomes are considered. For venous thromboembolism (VTE) risk, transdermal oestradiol (body-identical) is clearly safer than oral oestrogen regardless of whether the oestrogen itself is body-identical or conjugated equine. The route of administration matters more than the molecular identity for VTE risk. For breast cancer risk, the choice of progestogen appears to matter substantially. Evidence from the E3N study and several other observational datasets suggests that micronised progesterone combined with oestradiol carries a lower breast cancer risk than synthetic progestogen combinations, particularly those using norethisterone or MPA. The Million Women Study, which showed increased breast cancer risk with combined HRT, used primarily synthetic progestogen combinations, and its findings may not apply to micronised progesterone regimens. For cardiovascular outcomes including heart attack and stroke, starting HRT within ten years of menopause (the timing hypothesis) appears to be protective regardless of formulation type, while starting late in postmenopause may carry increased risk. These distinctions have led the British Menopause Society to recommend body-identical transdermal oestradiol with micronised progesterone as the preferred formulation for most women starting HRT.

Compounded Bioidentical Hormones: A Different Category

It is important to distinguish between regulated body-identical HRT (licensed pharmaceutical products such as Oestrogel, Sandrena, Evorel patches, and Utrogestan) and compounded bioidentical hormones (CBH), which are custom-mixed preparations produced by compounding pharmacies and not subject to the same regulatory oversight. Companies offering saliva testing, bespoke hormone creams, and individualized compounded combinations sit outside the licensed pharmaceutical framework and represent a different, and less evidenced, category. While some private practitioners advocate strongly for CBH, the British Menopause Society, Royal College of Obstetricians and Gynaecologists, and Medicines and Healthcare products Regulatory Agency have all expressed concern about the lack of standardisation, quality control, and evidence for CBH preparations. The potency of compounded preparations can vary significantly from batch to batch, and there is no long-term safety data for many compounded formulations. Women who want the benefits of body-identical hormones can access regulated, licensed body-identical HRT on the NHS or private prescription without needing to use unregulated compounded preparations.

How to Choose and What to Ask Your Doctor